A comprehensive review published in the World Journal of Pediatrics provides a systematic analysis of how chromodomain helicase DNA-binding (CHD) proteins regulate gene expression during heart development. The study synthesizes evidence from human genetics, animal models, and stem-cell systems to assign specific roles to different CHD family members, revealing a clear division of labor that could explain the origins of various congenital heart defects.
The review highlights that CHD7, the gene most frequently mutated in CHARGE syndrome, plays a dominant role in early structural heart formation. In contrast, CHD3 and CHD4 act as 'identity guardians,' ensuring heart cells commit to the correct fate during chamber formation. For CHD8, emerging evidence suggests it regulates later ventricular growth and functional maturation. The authors propose three testable models—parallel, sequential, and compensatory—to guide future research on how these remodelers might coordinate or compensate for each other across developmental time.
These findings have direct implications for clinical practice. For genetic screening, the study provides a clear priority: CHD7 for outflow-tract defects, CHD4 for chamber-patterning anomalies, and CHD8 for ventricular dysfunction. This prioritization can improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying their downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets. Future studies combining time-resolved multi-omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies.
The full review, titled 'Epigenetic control of cardiac development by CHD chromatin remodelers,' is available at https://doi.org/10.1007/s12519-026-01049-y. The research was supported by the National Key Research and Development Program of China and other grants.
